scholarly journals Cost‐Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First‐Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

2020 ◽  
Author(s):  
Dong Ding ◽  
Huabin Hu ◽  
Yin Shi ◽  
Longjiang She ◽  
Linli Yao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
The U.S

Phase II study of pazopanib plus interferon alfa as first-line therapy of advanced renal cell carcinoma: A Spanish Oncology Genitourinary Group (SOGUG) study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 4571-4571
Author(s):  
Xavier Garcia del Muro ◽  
Miguel Angel Climent ◽  
Jose Luis Perez-Gracia ◽  
Begona Mellado ◽  
JA Virizuela ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Interferon Alfa ◽  
Advanced Renal Cell Carcinoma ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

2015 ◽  
Vol 26 (6) ◽  
pp. 1118-1123 ◽  
Author(s):  
I.D. Davis ◽  
A. Long ◽  
S. Yip ◽  
D. Espinoza ◽  
J.F. Thompson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document